Brief: InDex Pharmaceuticals Q2 EBIT at SEK -86.9 Million
23/08/2023 07:02
Aug 23 (Reuters) - InDex Pharmaceuticals Q2 cash flow from operating activities SEK 80 million. * Q2 net income SEK 90 million * Q2 sales SEK 97.5 million * Q2 EBIT SEK -86.9 million
Recent news on Flerie AB
See all newsBrief: Flerie Q3 Net Asset Value SEK 3,113 Million
Brief: Flerie Portfolio Co Reports Positive Data From Clinical Proof-Of-Mechanism Study
Brief: Flerie Writes Down Value Of Holding In Empros Pharma
Brief: Nasdaq Approves Biosergen's Delisting Application
Brief: Flerie Approves Merger Plan For Flerie And Biosergen